Glaucoma Medication and Quality of Life After Phacoemulsification Combined with a Xen Gel Stent

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jun 24

PMID 35743517

Authors

Christian Pahljina

Stephanie Sarny

Lukas Hoeflechner

Thomas Falb

Gernot Schliessleder

Marlene Lindner

Domagoj Ivastinovic

Kaweh Mansouri

Ewald Lindner

Affiliations

Soon will be listed here.

Abstract

Glaucoma has a significant impact on quality of life. Here, we aimed to evaluate the influence of a reduction in glaucoma medications on quality of life and patient satisfaction after phacoemulsification combined with the Xen gel stent. We carried out a cross-sectional survey of patients who underwent phacoemulsification with the Xen gel stent at the Medical University of Graz, Austria. Quality of life was assessed using the German version of the Glaucoma Symptoms Scale (GSS)-questionnaire. Patients were also asked whether the operation reduced glaucoma medications and to indicate their overall satisfaction from 1 (totally discontented) up to 10 (totally contented). Questionnaires of 80 patients were evaluated. A total of 36 patients (45.0%) reported a reduction in glaucoma medications. Three items of the GSS were significantly better in patients who needed fewer glaucoma medications after the operation ("hard to see in daylight", 75.0 ± 31.1 vs. 57.7 ± 39.1, = 0.035; "hard to see in dark places", 81.1 ± 28.7 vs. 54.9 ± 41.2, = 0.002; and "halos around lights", 88.3 ± 25.9 vs. 68.8 ± 38.6, = 0.002). Patient satisfaction was significantly higher when the procedure led to a reduction in glaucoma medication (8.3 ± 2.0 vs. 6.8 ± 3.1; = 0.034). The reported quality of life and patient satisfaction were significantly better when phacoemulsification with the Xen gel stent reduced the number of glaucoma medications needed.

Citing Articles

Efficacy of XEN gel stent implantation combined with mitomycin C injection in the treatment of open-angle glaucoma: a meta-analysis.

Feng H, Zhang Z Int Ophthalmol. 2024; 44(1):410.

PMID: 39499348 PMC: 11538163. DOI: 10.1007/s10792-024-03306-3.

Managing the ocular surface after glaucoma filtration surgery: an orphan topic.

Agnifili L, Figus M, Sacchi M, Oddone F, Villani E, Ferrari G Graefes Arch Clin Exp Ophthalmol. 2023; 262(7):2039-2056.

PMID: 38091058 DOI: 10.1007/s00417-023-06333-5.

Postoperative Pain after Different Transscleral Laser Cyclophotocoagulation Procedures.

Falb T, Heidinger A, Wallisch F, Tomasic H, Ivastinovic D, Lindner M Int J Environ Res Public Health. 2023; 20(3).

PMID: 36768032 PMC: 9915327. DOI: 10.3390/ijerph20032666.

How Could Medical and Surgical Treatment Affect the Quality of Life in Glaucoma Patients? A Cross-Sectional Study.

Pastore M, Milan S, Agolini R, Egidi L, Agostini T, Belfanti L J Clin Med. 2022; 11(24).

PMID: 36555917 PMC: 9784022. DOI: 10.3390/jcm11247301.

References

Benitez-Del-Castillo J, Labetoulle M, Baudouin C, Rolando M, Akova Y, Aragona P . Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. Ocul Surf. 2016; 15(2):169-178. DOI: 10.1016/j.jtos.2016.11.003. View

Gillmann K, Bravetti G, Mermoud A, Rao H, Mansouri K . XEN Gel Stent in Pseudoexfoliative Glaucoma: 2-Year Results of a Prospective Evaluation. J Glaucoma. 2019; 28(8):676-684. DOI: 10.1097/IJG.0000000000001295. View

Janz N, Wren P, Lichter P, Musch D, Gillespie B, Guire K . Quality of life in newly diagnosed glaucoma patients : The Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001; 108(5):887-97; discussion 898. DOI: 10.1016/s0161-6420(00)00624-2. View

Skalicky S, Goldberg I, McCluskey P . Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2011; 153(1):1-9.e2. DOI: 10.1016/j.ajo.2011.05.033. View

Erb C, Gast U, Schremmer D . German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008; 246(11):1593-601. DOI: 10.1007/s00417-008-0881-9. View

Lee B, Gutierrez P, Gordon M, Wilson M, Cioffi G, Ritch R . The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998; 116(7):861-6. DOI: 10.1001/archopht.116.7.861. View

Gillmann K, Bravetti G, Rao H, Mermoud A, Mansouri K . Combined and stand-alone XEN 45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmol. 2020; 99(4):e531-e539. DOI: 10.1111/aos.14605. View

Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F . Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study. Sci Rep. 2018; 8(1):619. PMC: 5766542. DOI: 10.1038/s41598-017-19113-z. View

Camp A, Wellik S, Tzu J, Feuer W, Arheart K, Sastry A . Dry eye specific quality of life in veterans using glaucoma drops. Cont Lens Anterior Eye. 2015; 38(3):220-5. PMC: 5573601. DOI: 10.1016/j.clae.2015.02.001. View

10.

Abegao Pinto L, Vandewalle E, Gerlier L, Stalmans I . Improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combination. Ophthalmologica. 2014; 231(3):166-71. DOI: 10.1159/000356468. View

11.

Peters D, Heijl A, Brenner L, Bengtsson B . Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. Acta Ophthalmol. 2015; 93(8):745-52. PMC: 5014208. DOI: 10.1111/aos.12839. View

12.

Basilio A, Moura-Coelho N, Passos I, Cardoso M, Domingues I, Reina M . XEN implant and trabeculectomy medium-term quality of life assessment and comparison of results. Int J Ophthalmol. 2018; 11(12):1941-1944. PMC: 6288541. DOI: 10.18240/ijo.2018.12.11. View

13.

Lewis R . Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract Surg. 2014; 40(8):1301-6. DOI: 10.1016/j.jcrs.2014.01.032. View

14.

Rossi G, Pasinetti G, Scudeller L, Milano G, Mazzone A, Raimondi M . The Italian version of the Glaucoma Symptom Scale Questionnaire: translation, validation, and reliability. J Glaucoma. 2012; 22(1):44-51. DOI: 10.1097/IJG.0b013e318225406c. View

15.

Scelfo C, ElSheikh R, Shamim M, Abbasian J, Ghaffarieh A, Elhusseiny A . Ocular Surface Disease in Glaucoma Patients. Curr Eye Res. 2022; 48(3):219-230. DOI: 10.1080/02713683.2022.2041041. View

16.

Kobelt G, Jonsson B, Bergstrom A, Chen E, Linden C, Alm A . Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand. 2006; 84(3):363-71. DOI: 10.1111/j.1600-0420.2005.00621.x. View

17.

Silvio Di Staso , Agnifili L, Cecannecchia S, DI Gregorio A, Ciancaglini M . Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma. In Vivo. 2018; 32(2):211-220. PMC: 5905187. DOI: 10.21873/invivo.11227. View

18.

Lemij H, Hoevenaars J, van der Windt C, Baudouin C . Patient satisfaction with glaucoma therapy: reality or myth?. Clin Ophthalmol. 2015; 9:785-93. PMC: 4427261. DOI: 10.2147/OPTH.S78918. View

19.

Schallhorn S, Hettinger K, Teenan D, Venter J, Hannan S, Schallhorn J . Predictors of Patient Satisfaction After Refractive Lens Exchange With an Extended Depth of Focus IOL. J Refract Surg. 2020; 36(3):175-184. DOI: 10.3928/1081597X-20200211-01. View

20.

Konstantakopoulou E, Gazzard G, Vickerstaff V, Jiang Y, Nathwani N, Hunter R . The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics. Br J Ophthalmol. 2017; 102(5):599-603. DOI: 10.1136/bjophthalmol-2017-310870. View